Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Work In Process (2016 - 2020)

United Therapeutics' Work In Process history spans 11 years, with the latest figure at $28.1 million for Q1 2020.

  • For Q1 2020, Work In Process rose 6.84% year-over-year to $28.1 million; the TTM value through Mar 2020 reached $28.1 million, up 6.84%, while the annual FY2019 figure was $29.1 million, 3.93% up from the prior year.
  • Work In Process for Q1 2020 was $28.1 million at United Therapeutics, down from $29.1 million in the prior quarter.
  • Across five years, Work In Process topped out at $29.8 million in Q3 2019 and bottomed at $22.9 million in Q1 2017.
  • The 5-year median for Work In Process is $26.2 million (2016), against an average of $26.2 million.
  • The largest annual shift saw Work In Process rose 21.29% in 2016 before it fell 13.33% in 2017.
  • A 5-year view of Work In Process shows it stood at $24.9 million in 2016, then decreased by 3.21% to $24.1 million in 2017, then grew by 16.18% to $28.0 million in 2018, then grew by 3.93% to $29.1 million in 2019, then fell by 3.44% to $28.1 million in 2020.
  • Per Business Quant, the three most recent readings for UTHR's Work In Process are $28.1 million (Q1 2020), $29.1 million (Q4 2019), and $29.8 million (Q3 2019).